NEW YORK, July 31, 2023 -- Pfizer Inc. (NYSE: PFE) today provides the first of what will be periodic, as needed, updates regarding its ongoing efforts to recover from a destructive tornado that damaged predominantly the warehouse portion of its Rocky Mount manufacturing facility on July 19.

Site Operations:
- The current assessment shows no damage to our Rocky Mount site's production areas, lab rooms nor production equipment.
- There has been much work done to restore some of the basic operation of the site, including:
  - Full power restoration to all areas of the site
  - Cleaning of the suites and equipment is underway, as is a detailed engineering assessment on the facility, utilities, and equipment.
- Select colleagues and contractors in key functional areas required for restart are beginning to return on site.

Supply of Medicines:
- The Rocky Mount facility produces nearly 50 high-quality medicines including anesthesia, analgesia, and micronutrients. The major products are available in small volume presentations, such as ampules, vials, and syringes. These medicines make up about 25 percent of Pfizer’s sterile injectables used in U.S. hospitals, which equates to approximately 8 percent of the U.S. hospital supply.
- All medicines manufactured in Rocky Mount have been placed on allocation in the ordering systems to have equitable distribution of products and ensure availability to those in most need.
- The HiRise warehouse on-site was the most affected by the tornado.
  - Per the initial evaluation, all ~40,000 pallets of packaging supplies and finished goods stored in the HiRise warehouse were damaged.
  - All necessary supplies have been reordered for expedited delivery and Pfizer is in active contact with these suppliers.
- There were other warehouse locations that stored finished batches and work-in-process materials which were not physically damaged. Pfizer’s quality team is assessing these materials to determine which can be salvaged and released to the market.
- Pfizer has a storage location for inventory reconciliation and is working to secure temporary warehouse space in the vicinity, as an interim solution, until the warehouse on the Rocky Mount campus can be rebuilt.
- Pfizer is also exploring alternative manufacturing locations for production across its U.S. and international manufacturing facilities, and across the company’s partner network.
- Supply recovery has been prioritized on a subset of products that are medically important as well as those that have lower inventory.
- It’s important to note that Pfizer does not produce vaccines at the site, including our COVID-19 vaccine, sterile injectable oncology products, nor Bicillin.

Future updates will be provided as new information becomes available.

Pfizer and its colleagues are working closely with the U.S. Food and Drug Administration, other regulatory bodies, state and local officials on restoring the Rocky Mount facility to full operations and ensuring that there is minimum disruption to the supply of medicines as possible.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and
vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

DISCLOSURE NOTICE:
The information contained in this release is as of July 31, 2023. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s ongoing efforts to recover from the damage caused by a tornado to Pfizer’s Rocky Mount, North Carolina manufacturing facility that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, risks related to the ability to complete repairs to the facility, replacing damaged raw material and supplies and restoring full function to the site in the anticipated timeframe or at all; other business effects, including the effects of industry, market, economic, political or regulatory conditions; uncertainties regarding the impact of COVID-19; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

###